350 related articles for article (PubMed ID: 26051946)
1. Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S; Bowering V; Karakasis K; Oza AM
Expert Opin Drug Saf; 2015 Aug; 14(8):1305-16. PubMed ID: 26051946
[TBL] [Abstract][Full Text] [Related]
2. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
3. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
Nirsimloo R; Gourley C
Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
[TBL] [Abstract][Full Text] [Related]
5. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
6. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
7. Olaparib (Lynparza) for advanced ovarian cancer.
Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
[No Abstract] [Full Text] [Related]
8. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
10. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
[TBL] [Abstract][Full Text] [Related]
11. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
12. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
13. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Lorusso D; Bologna A; Cecere SC; De Matteis E; Scandurra G; Zamagni C; Arcangeli V; Artioli F; Bella M; Blanco G; Cardalesi C; Casartelli C; De Vivo R; Di Napoli M; Gisone EB; Lauria R; Lissoni AA; Loizzi V; Maccaroni E; Mangili G; Marchetti C; Martella F; Naglieri E; Parolin V; Ricciardi G; Ronzino G; Salutari V; Scarfone G; Secondino S; Spagnoletti I; Tasca G; Tognon G; Guarneri V
Support Care Cancer; 2020 May; 28(5):2435-2442. PubMed ID: 32048043
[TBL] [Abstract][Full Text] [Related]
14. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
16. Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
Chen Y; Zhang L; Hao Q
Arch Gynecol Obstet; 2013 Aug; 288(2):367-74. PubMed ID: 23619942
[TBL] [Abstract][Full Text] [Related]
17. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
18. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
Frampton JE
BioDrugs; 2015 Apr; 29(2):143-50. PubMed ID: 25899311
[TBL] [Abstract][Full Text] [Related]
19. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
